Recludix Pharma is a technology company.
Recludix Pharma has raised $60.0M across 1 funding round.
Recludix Pharma has raised $60.0M in total across 1 funding round.
Recludix Pharma has raised $60.0M in total across 1 funding round.
Recludix Pharma's investors include Frazier Healthcare Partners, New Enterprise Associates, Osage University Partners.
Recludix Pharma is a biotechnology company developing oral small molecule inhibitors targeting challenging protein domains, particularly SH2 domains in the JAK/STAT pathway, to treat inflammatory diseases like atopic dermatitis, asthma, COPD, and rheumatoid arthritis.[1][2][3] Its proprietary platform integrates custom DNA-encoded libraries (DELs), parallel structure-activity relationship (SAR) determination, and selective screening tools, enabling potent, selective inhibitors for previously undruggable targets.[1][3][4] The company serves patients with immunology and inflammation (I&I) conditions and certain cancers, solving the problem of imprecise pathway inhibition by JAK inhibitors or injectables like biologics, which often cause side effects or limited efficacy.[2][3][4] Key momentum includes a global STAT6 collaboration with Sanofi ($125M near-term payments, $1.2B+ milestones, U.S. profit-share option), IND-enabling studies for STAT6 (targeting 2025 IND), lead optimization for BTK and STAT3 wholly-owned programs, and recognition as a 2024 "Fierce 15" biotech.[1][2][4]
Recludix Pharma emerged from breakthroughs in targeting SH2 domains—key mediators in disease signaling recognized for over 30 years but historically undruggable—leveraging novel chemical approaches and integrated technologies.[3][5] The company was founded by an experienced management team of industry veterans, including former leaders from Seagen, Blueprint Medicines, and Lilly, who brought proven drug discovery success.[1] The idea crystallized around a proprietary platform first applied to SH2 inhibitors in inflammatory diseases, leading to rapid program advancement: a pivotal Sanofi partnership for STAT6 inhibitors validated the approach early, alongside wholly-owned STAT3 and BTK efforts.[1][3][4] Early traction came from generating high-quality leads and identifying opportunities across 120 human SH2 domains, positioning Recludix as a platform innovator in precision medicines.[2][3]
Recludix rides the wave of precision immunology, targeting validated JAK/STAT pathways where oral small molecules can displace injectables (e.g., IL-4/IL-13 biologics like STELARA® with >$10B sales) and safer-than-JAK inhibitors (> $4.7B sales despite safety issues).[4] Timing aligns with surging demand for oral alternatives in large I&I markets (atopic dermatitis, asthma, RA), amid biologics' limitations in convenience and dosing.[2][3][4] Market forces favoring it include SH2 domain drugging potential (120+ targets), platform scalability to oncology, and partnerships de-risking development.[1][2] Recludix influences biotech by pioneering SH2 inhibitors, enabling competitors to pursue similar undruggable targets and accelerating oral therapies in inflammation/oncology ecosystems.[3][5]
Recludix is poised for clinical milestones, with STAT6 IND likely in 2025 via Sanofi, advancing BTK/STAT3 to clinic, and expanding its platform to 5+ targets in I&I and oncology.[2][4] Trends like oral precision meds overtaking biologics/JAKs, plus AI/ML synergies in DEL screening, will propel growth amid $10B+ markets.[4] Its influence may evolve from platform pioneer to multi-product leader, potentially via IPO, buyout, or more Big Pharma deals—unlocking therapies for elusive targets and transforming patient access in inflammation. This positions Recludix as a Fierce 15 standout driving biotech's next precision era.[1]
Recludix Pharma has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series A in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $60.0M Series A | Frazier Healthcare Partners, New Enterprise Associates, Osage University Partners |